Christina Lake Cannabis Past Earnings Performance
Past criteria checks 0/6
Christina Lake Cannabis's earnings have been declining at an average annual rate of -24%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 77.3% per year.
Key information
-24.0%
Earnings growth rate
4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 77.3% |
| Return on equity | -31.5% |
| Net Margin | -30.4% |
| Last Earnings Update | 31 Aug 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Christina Lake Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Aug 23 | 12 | -4 | 3 | 0 |
| 31 May 23 | 11 | -3 | 4 | 0 |
| 28 Feb 23 | 10 | -2 | 4 | 0 |
| 30 Nov 22 | 10 | -2 | 4 | 0 |
| 31 Aug 22 | 9 | -5 | 3 | 0 |
| 31 May 22 | 7 | -4 | 4 | 0 |
| 28 Feb 22 | 5 | -6 | 4 | 0 |
| 30 Nov 21 | 4 | -7 | 5 | 0 |
| 31 Aug 21 | 2 | -3 | 6 | 0 |
| 31 May 21 | 0 | -6 | 6 | 0 |
| 28 Feb 21 | 0 | -4 | 5 | 0 |
| 30 Nov 20 | 0 | -3 | 5 | 0 |
| 31 Aug 20 | 0 | -1 | 4 | 0 |
| 31 May 20 | 0 | -3 | 3 | 0 |
| 29 Feb 20 | 0 | -2 | 2 | 0 |
| 30 Nov 19 | 0 | -2 | 2 | 0 |
| 31 Aug 19 | 0 | -2 | 2 | 0 |
| 31 May 19 | 0 | -1 | 1 | 0 |
| 28 Feb 19 | 0 | -1 | 1 | 0 |
| 30 Nov 18 | 0 | -1 | 1 | 0 |
| 31 Aug 18 | 0 | 0 | 0 | 0 |
| 31 May 18 | 0 | 0 | 0 | 0 |
| 28 Feb 18 | 0 | 0 | 0 | 0 |
| 30 Nov 17 | 0 | 0 | 0 | 0 |
| 31 Aug 17 | 0 | 0 | 0 | 0 |
| 31 May 17 | 0 | 0 | 0 | 0 |
| 28 Feb 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
| 31 Aug 16 | 0 | 0 | 0 | 0 |
| 31 May 16 | 0 | 0 | 0 | 0 |
| 29 Feb 16 | 0 | 0 | 0 | 0 |
Quality Earnings: CLC is currently unprofitable.
Growing Profit Margin: CLC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLC is unprofitable, and losses have increased over the past 5 years at a rate of 24% per year.
Accelerating Growth: Unable to compare CLC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: CLC has a negative Return on Equity (-31.52%), as it is currently unprofitable.